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A reduced frequency of HLA-DQ6 in patients with a positive direct
antiglobulin test (DAT) was previously reported but race was undis-
closed. Therefore, we investigated a total of 275 patients (80
Caucasian, 113 African American, and 82 Mexican American) and
518 normal controls (205 Caucasian, 208 African American, and 105
Mexican American).  These were typed for class II HLA antigens
using molecular techniques.  A DAT was performed on each patient’s
red cells drawn into EDTA using both mouse and rabbit polyspecific
reagents.  Of 275 patients tested, 73 (27%) had a positive DAT (12
Caucasians, 35 African Americans, and 26 Mexican Americans).  We
found that 5 (42%) Caucasian patients and 103 (50%) Caucasian con-
trols possessed the DQB*06 allele (p = .56).  In the African American
group, 15 (43%) patients and 91 controls (44%) were DQB*06 posi-
tive (p = .92).  Six Mexican American patients (23%) and 21 controls
(20%) had the DQB*06 allele (p = .72).  This article underscores the
need to use race-matched controls when genetic disease associations
are sought. Immunohematology 2000; 16:74–7.
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The major histocompatibility complex (MHC) is a set
of genes whose molecular products, the human leuko-
cyte antigens (HLA), play a central role in the control of
the immune response. These genes are closely linked
and are inherited as a unit or haplotype. The MHC genes,
which code for the three classes of HLA antigens, are
located on chromosome 6. The class II genes are known
as the D region and the individual loci within this area
are designated as DM, DO, DP, DQ, and DR. The MHC
genes are among the most polymorphic in the human
genome,which makes it highly unlikely that any two ran-
dom individuals will express identical sets of MHC
molecules on their cells.
The MHC class II molecules are expressed on B lym-
phocytes, thymic epithelial cells, and dendritic cells but
can also be induced by certain activating factors to
appear on such cells as macrophages. Class II molecules
are dimers made up of an alpha and a beta chain. Each
has both a variable and an invariable region. The prima-
ry function of the class II molecules is to present foreign
antigenic peptides to CD4 T-helper cells. Those T cells
with the appropriate receptor bind to the invariable por-
tion of the class II molecule,become activated,and assist
B cells in production of antibody directed against a spe-
cific foreign antigen. In this way an immune response is
initiated against exogenous antigens such as bacteria and
viruses that have invaded “normal”body cells.
Since the early 1990s, PCR amplification of HLA class
II genes with single-stranded oligonucleotide detection of
polymorphic sites in the DNA fragment has become com-
mon. This DNA-based method for molecular typing of all
classes of HLA antigens allows for a more precise identi-
fication of the unique alleles present in an individual
compared with serologic techniques used in the past.
Certain haplotypes of the HLA antigens are associated
with particular diseases. For example, the HLA alleles
DR2 and DR3 are associated with an increased frequen-
cy of systemic lupus erythematosus (SLE).1,2 Associations
have been made between HLA-DR and HLA-DQ antigens
and other autoimmune diseases, including rheumatoid
arthritis, diabetes mellitus, multiple sclerosis, and
hemolytic anemia.3
Autoimmune hemolytic anemia (AIHA) is often a sec-
ondary feature of multisystem rheumatic diseases, par-
ticularly SLE. It also may arise in the setting of  human
immunodeficiency diseases, such as AIDS.4 AIHA occurs
when there is an increased destruction of red blood cells
(RBCs) coated with anti-RBC autoantibodies, which are
cleared prematurely by the liver and occasionally by the
spleen. The bone marrow becomes stressed and cannot
adequately compensate for the excessive loss of  RBCs.
The autoantibodies, which cause anemia, can be classi-
fied into two types: Cold reactive autoantibodies react
optimally at temperatures less than 37° C and are of the
IgM variety. Warm reactive autoantibodies are usually
IgG, bind to RBCs best at 37° C, and are the most fre-
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quent cause of anemia. In association with other
rheumatic diseases,AIHA can be detrimental to the out-
come of an illness.
One study of patients with hemolytic anemia found a
reduced frequency of the class II HLA-DQ6 allele.5 In
this study the hemolysis was accompanied by a positive
DAT. The study concluded that DAT-positive individuals
were less likely to possess the DQB*06 allele and people
who did possess the allele may be protected from clini-
cally relevant RBC autoantibodies. The study design for
the research included 31 samples from patients  with a
positive DAT, most of whom displayed evidence of clini-
cal hemolysis. Thirteen of those patients had an associ-
ated disease,ten had hemolysis only,and eight were DAT-
positive normal blood donors with no signs of
hemolysis. The control group consisted of 85 DAT-nega-
tive cadaver organ donors. The race-ethnicity of the
patients and controls was not disclosed but was said to
include minorities. The patients and controls were typed
for HLA-DR and HLA-DQ class II alleles. Results showed
that only 13 percent of the DAT-positive patients pos-
sessed the DQB*06 allele, compared with 53 percent of
the DAT-negative normal controls (p = 0.059,RR = 0.23).
We examined a much larger group of patients and
controls, giving special consideration to race-ethnicity
because it has been proven that different racial-ethnic
groups have a propensity for certain genetic haplo-
types.6 Our purpose was to determine HLA-DQB gene
frequency in three populations and to ascertain whether
an association between the HLA-DQB*06 allele and
hemolytic anemia with a positive DAT existed.
Materials and Methods
Test subjects
Individuals recruited for this study were approved by
the Committee for the Protection of Human Subjects.
Three racial-ethnic groups were chosen for our cohort:
Caucasian, African American, and Mexican American,
representing 275 patients and 518 normal controls. Of
the Caucasian group, 80 were patients and 205 were
controls. The African American group had 113 patients
and 208 controls, whereas the Mexican American group
contained 82 patients and 105 controls. Each patient
was diagnosed as having either SLE (197) or AIDS (78),
two diseases in which a positive DAT is a frequent find-
ing.7 Approximately 10 percent of the SLE patients had
clinical symptoms of hemolysis (G. Alarcon, personal
communication).
Direct antiglobulin testing (DAT)
DATs were performed using the standard tube agglu-
tination method. A 3 to 5% washed cell suspension was
made from EDTA blood samples for each patient and
control tested. One drop of the cell suspension and 2
drops of rabbit or murine polyspecific anti-human glob-
ulin (Gamma Biologicals, Houston, TX) were mixed,
then centrifuged for 15 seconds at 3000 rpm.
Agglutination was examined macroscopically with the
aid of an agglutination viewer, and results were graded
w+ to 4+.8 Positive DATs were characterized using
monospecific murine and rabbit anti-IgG reagents and a
murine anti-C3b-C3d reagent (Gamma Biologicals).
Because we have noted a number of  falsely positive
reactions when using rabbit polyspecific antiglobulin
reagents (unpublished data), only those samples that
were positive for IgG were included in this study.
HLA typing
Genomic DNA was isolated from peripheral blood
leukocytes by proteinase K digestion  followed by  phe-
nolchloroform extraction.9 HLA class II genotyping of
HLA-DRB1, DQA1, and DQB1 alleles was performed by
oligotyping as previously described, with modifications
added to type for the currently recognized DRB1
specifcities.10,11 High resolution HLA-DRBl typing was
carried out using a two-step method. First, generic DRB
typing was performed to distinguish the DR1, DR2,
DR3/6/11, DR 8/12, and DR4 allelic groups as well as
DRB1*0701, 0901, 1001; DRB3*0101,*02/03; and
DRB4*0101. Subsequently, group-specific amplifica-
tion of HLA-DR1, DR2, DR3/6/8/11/12, and DR4 alle-
les was carried out using the appropriate primers for
high resolution typing with 18-mer oligonucleotide
probes known to determine all alleles at the respective
loci.
Statistical analysis
Statistical analysis for determining the frequency of
the DQB*06 allele in both patients and race-ethnicity–
matched  controls was performed using a two-by-two
contingency table (chi-square analysis) with the EPI-
INFO statistical program. Statistical significance was
determined by Fisher’s exact probability test.
Results
It was found that 73 of the 275 patients (27%) were
DAT-positive. Twelve of the 80 patients in the Caucasian
group (15%), 35 of the 113 African American patients
(31%), and 26 of the 82 Mexican American patients
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(32%) had positive DAT results. All 518 members of the
control group were DAT-negative (Table 1).
Table 1. Total patients and controls grouped by race-ethnicity
Patients with a Controls with a
No. of  patients positive DAT* negative DAT
Caucasian 80 12 (15%) 205
African American 113 35 (31%) 208
Mexican American 82 26 (32%) 105
Totals 275 73 (27%) 518
*Direct antiglobulin test
Controls and DAT-positive patients were then tested
for the presence of the HLA-DQB*06 allele using the
DNA-based method for class II HLA typing. Of those
patients with a positive DAT, 42 percent of Caucasians
possessed the DQB*06 allele as did 50 percent of the
Caucasian DAT-negative controls. In the African
American group,43 percent of DAT-positive patients dis-
played the DQB*06 allele as well as 44 percent of the
African American controls. Twenty-three percent of the
DAT-positive Mexican American patients tested positive
for the DQB*06 allele compared with 20 percent of the
Mexican American controls (Table 2). A chi-square anal-
ysis of these data revealed that differences were not sta-
tistically significant (p > .5).
Table 2. Frequency of HLA-DQB*06 in DAT-positive patients and DAT-
negative controls
Patients with a Controls with a 
positive DAT* negative DAT p-value
Caucasian 5 (42%) 103 (50%) .56
African American 15 (43%) 91 (44%) .92
Mexican American 6 (23%) 21 (20%) .72
*Direct antiglobulin test
Discussion
There appeared to be racial-ethnic differences in the
DAT results that have not been reported previously.
Twice as many African American and Mexican American
patients (31% and 32%, respectively) had positive DATs
than did the Caucasian patients (15%). A possible expla-
nation for this is that African American and Hispanic SLE
patients tend to have more severe disease than do
Caucasian SLE patients.12 In our study, 72 African
American and 71 Mexican American patients were diag-
nosed with SLE. The high frequency of positive DATs in
those ethnic groups may be due to high levels of
immune complexes that may accompany the disease.
There is a generalized reduction in the Mexican
American population for the DQB*06 allele. Likewise,
there appears to be no association between the DQB*06
gene and a positive DAT. Conclusions from a previous
investigation may have been skewed due to the inap-
propriate matching of controls used in that study group.
Thus, this article underscores the need to use race-
ethinicity-matched controls when investigating genetic
associations with diseases.
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